- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01764087
A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors
An Open-label Phase I/II Study of KX2-391 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Anticipado)
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Seoul, Corea, república de, 110-744
- Reclutamiento
- Seoul National University Hospital
-
Contacto:
- Eunkyung Kim
- Número de teléfono: +82-2-2072-7616
-
-
Gyeonggi-Do
-
Seongnam, Gyeonggi-Do, Corea, república de, 463-707
- Reclutamiento
- Seoul National University Bundang Hospital
-
Contacto:
- Yun Jin Kim
- Número de teléfono: +82-31-787-1421
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
Phase I Portion:
- Diagnosis of solid tumors on histopathological examination or cytological examination for which no standard of care is available or conventional treatment modalities have no therapeutic effect at the time of entering into the study
Phase II Portion:
- Diagnosis of advanced/metastatic/recurrent stomach cancer or breast cancer on histopathological examination or cytological examination for which no standard of care is available or conventional treatment modalities have no therapeutic effect at the time of entering into the study
- Subjects with stomach cancer without prior taxane therapy
- Subjects with breast cancer with prior taxane therapy
- (Optional) Providing exploratory biomarker informed consent form to obtain archival tumor tissue and/or new tumor biopsy sample
Common:
Based on clinical screening,
① If radiotherapy was given, at least 4 weeks should have passed from the last treatment date and the patient should have recovered from the toxicity (However, for limited regional radiotherapy, at least 2 weeks from the last treatment date)
② If hormonal therapy was given, at least 2 weeks should have passed from the last treatment date and the patient should have recovered from the toxicity.
③ If chemotherapy was given, at least 3 weeks should have passed from the last treatment date and the patient should have recovered from the toxicity (However, for nitrosourea or mitomycin, at least 6 weeks)
- Aged ≥ 20 years
- ECOG (Eastern Cooperative Oncology Group) ≤ 2
- Life expectancy ≥ 12 weeks
Should meet the followings,
① Bone marrow function ANC (Absolute Neutrophil Count) ≥ 1.5 X 109/L, PLT (Platelet Count) ≥ 100 X 109/L, Hemoglobin ≥ 9.0 g/dl (In the case of hemoglobin of < 9.0 g/dl, the patient can be enrolled if the value is reversed to ≥ 9.0 g/dl.)
② Kidney function Creatinine Clearance > 50 ml/min or Serum Clearance ≤ 1.5 mg/dl
③ Liver function AST (Aspartate Aminotransferase)/ALT (Alanine Aminotransferase)/ALP (Alkaline Phosphatase) ≤ 3.0 X UNL and Total bilirubin ≤ 2.0 mg/dl (With bone metastasis, ALP ≤ 5.0 X UNL)
- At least one measurable lesions with the length of the longest diameter of ≥ 10 mm on spiral CT or multidetector CT or ≥ 20 mm on conventional CT
- Subjects who voluntarily consent to participate in this study and sign the written informed consent form
Exclusion Criteria:
- Uncontrolled central nervous system metastasis
- Malignant ascites requiring surgical treatment
- Subjects who have blood malignancies including leukemia; or who have received or will receive bone marrow transplantation
Severe concurrent diseases as follows,
① History of unstable angina, heart failure, atrial or ventricular arrhythmia requiring pharmacological treatment, or having received treatment for myocardial infarction within 6 months (however, may be included under the judgment of the investigator if medically controlled), heart failure of Class III or IV by New York Heart Association Classes, or left ventricular ejection fraction of < 40%
② Receiving therapeutic dose administration of coumarin-type anticoagulants (however, up to 2 mg daily is permitted for line opening)
③ Uncontrolled diabetes (fasting plasma glucose > 2.0 X UNL), severe hypertension, thyroid disorder and active infectious disease
④ Psychiatric or neurological history including dementia or epilepsy which may threaten the compliance with this protocol
⑤ A condition not allowing oral application of tablet formulation, and any clinically significant gastrointestinal abnormalities which may interfere with taking, passing or absorption of the study drug
- Using disallowed concomitant medications (strong CYP3A4 (Cytochrome P450 3A4) inhibitors or inducers) (When a patient is using any of the disallowed concomitant medications below, wash-out of 1 week from the medication date is required)
- Received other investigational product within 4 weeks prior to the administration of this study drug
- Pregnant or breast-feeding women (however, women with 12 months of natural (spontaneous) amenorrhea or surgical bilateral oophorectomy (alone or with hysterectomy) at least 6 weeks ago, with appropriate clinical profile (e.g., appropriate age, history of vasomotor symptoms), will be considered women postmenopausal and of non-childbearing potential. In the case of oophorectomy alone, a woman will be considered to be of non-childbearing potential only if her reproductive condition is confirmed by follow-up hormone level assessment)
- History of hypersensitivity to paclitaxel, compounds with similar chemical structure, or cremophor (polyoxyethylated castor oil) ingredient
- Neuropathy of grade ≥ 3 based on clinical screening
- Known history of hepatitis B or C and known history of HIV serum positive
- Others unable to participate in the study under the judgment of the investigator
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: KX2-391 and Paclitaxel
The phase I portion is a standard, three-patient per cohort, dose escalation schedule will be used. 3 or 6 subjects with solid tumor per dose group will likely be necessary to determine the MTD of KX2-391 in combination with weekly paclitaxel. With paclitaxel dose fixed at 80 mg/m2/weekly, KX2-391 treatment will be started at 20 mg dose once daily (QD) The phase II portion of this trial has a design to determine the efficacy of KX2-391 when administered in combination with paclitaxel in 20 subjects with stomach cancer and 20 subjects with breast cancer |
A treatment cycle in phase I will consist of 28 days, according to the following schedule: KX2-391 20 mg PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle. The trial will initially test the combination of weekly paclitaxel and KX2-391 given PO, once daily , continuously. In case of 2 dose-limiting toxicities (DLT) in the first cohort, this intervention will be terminated A treatment cycle in phase II will consist of 28 days, according to the following schedule: KX2-391 MTD PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Dose-limiting Toxicities (DLTs) in Phase I Portion
Periodo de tiempo: From start of the treatment to end of cycle 1, which are 4 weeks
|
Maximum tolerated dose (MTD) of KX2-391 in combination with weekly paclitaxel as determined by number of participants With DLTs related to KX2-391 in combination with weekly paclitaxel
|
From start of the treatment to end of cycle 1, which are 4 weeks
|
Tumor Overall Response Rates (ORRs) in Phase II Portion
Periodo de tiempo: In every 2 cycles up to end of the treatment, an expected average of 16 weeks
|
The efficacy (overall response rate; ORR; complete response (CR) + partial response (PR)) of KX2-391 in combination with weekly paclitaxel at the MTD established during the phase I portion of this trial based on Response Evaluation Criteria in Solid Tumor (RECIST) 1.1
|
In every 2 cycles up to end of the treatment, an expected average of 16 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Pharmacokinetic (PK) Evaluation in Phase I Portion
Periodo de tiempo: Time points at day 0, 1 and 8 in cycle 1
|
PK parameters, including but not limited to, plasma concentration, AUC (Area Under Curve) 0-t, Cmax, Tmax, and T1/2 of KX2-391 alone and in combination with weekly paclitaxel
|
Time points at day 0, 1 and 8 in cycle 1
|
The Preliminary Efficacy Data in Phase I Portion
Periodo de tiempo: In every 2 cycles up to end of the treatment, an expected average of 8 weeks
|
The preliminary efficacy of KX2-391 in combination with weekly paclitaxel as determined by ORRs based on RECIST 1.1
|
In every 2 cycles up to end of the treatment, an expected average of 8 weeks
|
Safety in Phase II Portion
Periodo de tiempo: From start of the treatment to end of the treatment, an expected average of 16 weeks
|
Adverse events and their frequency, duration and severity, physical examination, laboratory parameters, vital signs and ECG change monitoring as determined based on CTCAE (Common Toxicity Criteria for Adverse Effects) 4.03
|
From start of the treatment to end of the treatment, an expected average of 16 weeks
|
The Efficacy Data in Phase II Portion
Periodo de tiempo: Up to die, an expected average of 24 weeks
|
Overall survival (OS), progression free survival (PFS), time to tumor progression (TTP) and duration of response
|
Up to die, an expected average of 24 weeks
|
Pharmacokinetic (PK) Evaluation in Phase II Portion
Periodo de tiempo: Time points at day 1 and 8 in cycle 1
|
PK parameters, including but not limited to, plasma concentration, AUC0-t, Cmax, Tmax, and T1/2 of KX2-391 alone and in combination with weekly paclitaxel
|
Time points at day 1 and 8 in cycle 1
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Pharmacodynamic (PD) Evaluation in Phase I Portion
Periodo de tiempo: Time points at day 0 and 1 in cycle 1
|
Pre-dose and post-dose tubulin inhibition in peripheral blood monocytes extracted from blood samples, as measured by immunofluorescence staining
|
Time points at day 0 and 1 in cycle 1
|
Exploratory Biomarker Evaluation in Phase II Portion
Periodo de tiempo: Time points at day -6 and day 0
|
Pre-dose and post-dose Src signaling inhibition (p-Src and Ki-67) in archival tumor tissue and new biopsy sample, as measured by immunohistochemistry
|
Time points at day -6 and day 0
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Seock-Ah Im, M.D., Ph.D., Seoul National University Hospital
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Neoplasias por sitio
- Neoplasias Gastrointestinales
- Neoplasias del Sistema Digestivo
- Enfermedades Gastrointestinales
- Enfermedades del Estómago
- Neoplasias
- Neoplasias de Estómago
- Mecanismos moleculares de acción farmacológica
- Inhibidores de enzimas
- Agentes antineoplásicos
- Moduladores de tubulina
- Agentes antimitóticos
- Moduladores de mitosis
- Agentes antineoplásicos, fitogénicos
- Paclitaxel
- Tirbanibulin
Otros números de identificación del estudio
- HM-KXI-101
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer de mama
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University y otros colaboradoresTerminadoLa guía de aplicación clínica de Conebeam Breast CTPorcelana
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos
Ensayos clínicos sobre KX2-391 and Paclitaxel
-
Athenex, Inc.TerminadoQueratosis actínicaEstados Unidos
-
Athenex, Inc.TerminadoLinfoma | Tumores sólidosEstados Unidos
-
Almirall, S.A.Athenex, Inc.TerminadoQueratosis actínicaEstados Unidos
-
Almirall, S.A.Athenex, Inc.Terminado
-
Kinex Pharmaceuticals Inc.TerminadoLeucemia mielógena agudaEstados Unidos
-
Athenex, Inc.TKL Research, Inc.Terminado
-
Athenex, Inc.TerminadoCáncer de próstata metastásico óseo resistente a la castraciónEstados Unidos
-
Almirall, S.A.Athenex, Inc.TerminadoQueratosis actínicaEstados Unidos
-
Roswell Park Cancer InstituteTerminadoLinfoma | Cáncer de intestino delgado | Tumor sólido adulto no especificado, protocolo específico | Trastorno linfoproliferativoEstados Unidos